KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Cash: 2010-2025

Historic Change in Cash for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to -$21.8 million.

  • Emergent BioSolutions' Change in Cash fell 125.53% to -$21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 35.28%. This contributed to the annual value of -$6.1 million for FY2024, which is 98.85% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Change in Cash of -$21.8 million as of Q3 2025, which was down 118.44% from $118.2 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Change in Cash peaked at $401.6 million during Q4 2022, and registered a low of -$344.2 million during Q2 2023.
  • Moreover, its 3-year median value for Change in Cash was -$8.0 million (2024), whereas its average is -$35.8 million.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 636.50% in 2021, then spiked by 10,775.00% in 2024.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Change in Cash stood at $172.3 million in 2021, then skyrocketed by 133.08% to $401.6 million in 2022, then crashed by 94.05% to $23.9 million in 2023, then tumbled by 312.55% to -$50.8 million in 2024, then tumbled by 125.53% to -$21.8 million in 2025.
  • Its last three reported values are -$21.8 million in Q3 2025, $118.2 million for Q2 2025, and $47.2 million during Q1 2025.